12 Dec, 10:34 - Indian

SENSEX 81507.79 (-0.02)

Nifty 50 24612.45 (-0.12)

Nifty Bank 53359.35 (-0.06)

Nifty IT 45863.9 (1.13)

Nifty Midcap 100 59230.45 (-0.11)

Nifty Next 50 73222.3 (-0.10)

Nifty Pharma 22293.5 (-0.04)

Nifty Smallcap 100 19599.05 (-0.30)

12 Dec, 10:34 - Global

NIKKEI 225 39881.96 (1.29)

HANG SENG 20414.37 (1.29)

S&P 6096.75 (-0.13)


Corporate News

You are Here : Home > News > Corporate News >

(06 Sep 2024, 13:01)

Sun Pharma and Israel-based Moebius Medical announce USFDA grant of Fast Track designation to MM-II

A potential treatment for patients suffering from Osteoarthritis


Sun Pharmaceutical Industries and Israel-based Moebius Medical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MMII is underway.

The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review.

“As we enter Phase 3 development, we are very encouraged by the FDA's decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis,” said Marek Honczarenko, MD, PHD, Senior Vice President, Head Global Development at Sun Pharma.


More News
More Company News View Company Information